Heliyon (Jun 2023)
Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
- Cécile Hérate,
- Romain Marlin,
- Franck Touret,
- Nathalie Dereuddre-Bosquet,
- Flora Donati,
- Francis Relouzat,
- Laura Junges,
- Mathilde Galhaut,
- Océane Dehan,
- Quentin Sconosciuti,
- Antoine Nougairède,
- Xavier de Lamballerie,
- Sylvie van der Werf,
- Roger Le Grand
Affiliations
- Cécile Hérate
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Romain Marlin
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Franck Touret
- Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, 27 Bd Jean Moulin, 13005, Marseille, France
- Nathalie Dereuddre-Bosquet
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Flora Donati
- Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Molecular Genetics of RNA Viruses Unit, 25-28 Rue du Dr Roux, 75015, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 25-28 Rue du Dr Roux, 75015, Paris, France
- Francis Relouzat
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Laura Junges
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Mathilde Galhaut
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Océane Dehan
- Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Molecular Genetics of RNA Viruses Unit, 25-28 Rue du Dr Roux, 75015, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 25-28 Rue du Dr Roux, 75015, Paris, France
- Quentin Sconosciuti
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France
- Antoine Nougairède
- Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, 27 Bd Jean Moulin, 13005, Marseille, France
- Xavier de Lamballerie
- Unité des Virus Émergents (UVE), Aix Marseille Université, IRD 190, INSERM 1207, 27 Bd Jean Moulin, 13005, Marseille, France
- Sylvie van der Werf
- Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Molecular Genetics of RNA Viruses Unit, 25-28 Rue du Dr Roux, 75015, Paris, France; Institut Pasteur, Université Paris Cité, National Reference Center for Respiratory Viruses, 25-28 Rue du Dr Roux, 75015, Paris, France
- Roger Le Grand
- Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), 18 route du Panorama, 92265, Fontenay-aux-Roses, France; Corresponding author. Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France, 18 route du Panorama, 92265, Fontenay-aux-Roses, France.
- Journal volume & issue
-
Vol. 9,
no. 6
p. e16664
Abstract
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.
